1. Siteman Investment Program
Karen Kharasch, Executive Director

2. Disclosure Information
2015 CCAF Annual Meeting
I have no financial relationships to disclose.

3. SITEMAN INVESTMENT PROGRAM
40k / year from the CCSG
We have significant philantrophy and multiple major events.
Barnard Trust

4. Siteman Investment Program (SIP)
2009 – 2014
Profile 83
$12.4 million
SIP awarded grants
$ 39.2 million
71 Leveraged grants
107 7
Total of 71 subsequent grants 3:1
Our CCSG developmental fund support is $40,000 per year, which is significantly augmented by philanthropy assets to provide adequate pilot funding. Combined annual awards to SCC members from the SIP average just over $2 million to support and encourage collaborative pre-clinical, translational and innovative cancer-related projects. From , SCC has awarded a total of $10.9 million to 67 investigators representing all seven programs. Our faculty leveraged $34.7 million to date in direct costs in external funding including 21 NCI awards: $22 million (63% of total leveraged). Mechanisms require or encourage use of SRs and to promote inter-programmatic research, co-investigators from at least two different programs. The SIP has been highly successful in developing new collaborations between program members and allows investigators to generate preliminary data which can be used to leverage additional external, peer-reviewed funding. 32
45% 3 4% 36
51%

5. Evaluation of RFAs and Review Process
Difficulties
5 annual scientific review committees
Extreme difficulty finding reviewers
Faculty feedback:
Uncertain what the reviewers/Senior Leadership wants
Transparency
Consistency of announcement
Competitive renewals for all 2 year awards

6. New SIP Model
Streamline & Transparent
The following current Siteman RFAs will now be incorporated into the new review model
SCC Research Development Awards (RDA)
Breast Cancer Program Career Development (CDA)
Breast Research Development Awards
Cancer Frontier Fund (CFF)
ACS-IRG will be a sub-study section
Devised by past chairs of our review committees, Assoc. Directors of Basic and translational sciences

7. Assumptions Total awards are dependent on philanthropy
The number of awards and the award amount may increase or decrease each year dependent on SCC philanthropy
Total awards are dependent on scientific merit
The number of awards and the award amount may increase or decrease each year dependent on scientific merit of the applicants at each study section

8. Purpose Discovery, diagnosis, treatment and public health
Create an agile study section model in order to provide pilot funding for SCC members in discovery, diagnosis, treatment and public health
Discovery, diagnosis, treatment and public health
New diagnostic tests, imaging technology, drug, vaccine, or other cancer therapy
Accelerate discoveries to test and verify pioneering options
Produce data that provide the basis for future applications (such as R01s, R21s, DOD, SPOREs, PPGs, etc.) or the opportunity for business creation and venture funding
Catalyze discoveries by building bridges among disciplines and researchers in St. Louis (WU, WUSM, SLU and soon UMSL)

9. for 2 years (direct costs)
Total award
for 2 years (direct costs)
# of awards 
Cycle Cycle 2
Announced
January 1
July 1
Due date
May 1
October 1
Start date
Pre-R01
$400,000 2
Pre-SPORE/PPG
$ 800,000 1
Multi-PI Pre-R01
Danforth/Consortium
$ 200,000
Total awarded for 2 years
$ 1,800,000 5
4 types of RFAs will be offered:
Pre-R01 Program for WUSTL Medical School faculty and a Pre-R01 Program for SLU Consortium and Danforth Campus faculty
Multi-PI Pre-R01 for all Siteman Cancer Center members
Pre-SPORE/PPG program for all Siteman Cancer Center members

10. SIP Study Section Structure
Representatives from all Programs
reviewers
Recommended and assigned by each program leaders
Rotating Chairs by program
Internal competition reviews as required
Ad hoc leadership: Associate Directors of Basic Science, Translation, Shared Resources and Executive Director

11. SIP Study Section Structure
Rotation of Reviewers
Each review cycle will have 14 of the 21 reviewers
Ad hoc reviewers as required
Reviewers will serve 3 year term
Required to participate in 4 of the 6 reviews in the three year period
Rotate off after 4 study sections
Allows reviewers to take off a cycle to submit

12. Funds Allotment Review
Funding Review
Chairs of the Study Section
Associate Directors of Basic, Translation Science and Shared Resources
Executive Director
VP BJH Foundation
BJH Foundation Board member
Pedal the Cause Executive Director
Business Director

13. Budget and Scientific Review
Business Director & staff have access to all Siteman SIP accounts
Science
Scientific progress is reported once a year.
We can see accruals

14. www. siteman.wustl.edu